This post was written by Melanie Riehl BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination to discuss the best biotech plays outside of the GLP-1 ...
Republic Business on MSN20h
Obesity drug developer BioAge seeks up to $587 milllion valuation in US IPOObesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...
Check the time stamp on this data. Updated AI-Generated Signals for Global Partners Lp Representing Limited Partner Interests ...
Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...
The GLP-developed warehouses were disposed of due to "the stabilised nature of the portfolio, its attractive quality and ...
Kepler Capital analyst Aymeric Poulain maintained a Hold rating on Saab AB (0GWL – Research Report) on September 17 and set a price ...
In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...
Prologis is pivoting to AI infrastructure, aiming to capitalize on higher-margin opportunities. Read why I think PLD stock is ...
At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...
Financial stocks rose in late Friday afternoon trading, with the NYSE Financial Index adding 0.5% and the Financial Select Sector SPDR Fund (XLF) up 0.3%. The Philadelphia Housing Index climbed 2.6%, ...
At Fierce Healthcare, we keep track of all the venture capital being funneled into the health tech and digital health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback